To explore the application value of tumor markers carcinoembryonic antigen and cytokeratin 19 fragment in the progression and prognosis of middle-advanced non-small cell lung cancer. Clinical data of 97 patients initially diagnosed with lung lesions in our hospital from January 2018 to December 2019 were collected and divided into the lung cancer group and benign lesion group. There were 52 patients diagnosed with stage I or II lung cancer by computed tomography and clinical diagnosis in the lung cancer group and 45 patients with benign lesions in the benign lesion group. The levels of serum tumor markers were detected by electrochemiluminescence immunoassay. The results showed that the levels of carcinoembryonic antigen and cytokeratin 19 were significantly higher in the lung cancer group compared with the benign lesion group and the difference was statistically significant (p<0.05). Both carcinoembryonic antigen and cytokeratin 19 can be used in the diagnosis of squamous cell carcinoma and adenocarcinoma. The sensitivity of the combined detection was significantly higher than that of the single detection, while the specificity of the combined detection was significantly lower than that of carcinoembryonic antigen alone (p<0.05). In lung cancer with positive combined detection, the proportion of adenocarcinoma was significantly higher than that of squamous cell carcinoma. When cytokeratin 19 was positive and carcinoembryonic antigen was negative, the proportion of squamous cell carcinoma was significantly higher than that of adenocarcinoma. Serum carcinoembryonic antigen and cytokeratin 19 were abnormally highly expressed in non-Small cell lung cancer patients, which are useful for clinical diagnosing, treatment planning, efficacy monitoring, and prognosis evaluation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.